Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH binds to receptors on ovarian granulosa cells, stimulating follicle development and estrogen production. LH binds to receptors on theca and luteal cells, supporting androgen conversion to estrogen and triggering ovulation and luteinization. Together they coordinate the hormonal cascade required for successful oocyte maturation.

The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian response, treatment protocol, and clinical goals. No standard dosing regimen is provided in public information.

Meriofert is intended for use before conception to facilitate ovulation. Its safety in established pregnancy or during breastfeeding has not been established, and it is generally not recommended in these situations unless specifically advised by a specialist.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Meriofert contains both recombinant FSH and LH, offering a combined hormonal profile. Compared with urinary‑derived preparations that may contain variable LH activity, Meriofert provides a consistent, defined ratio of FSH to LH, similar to other recombinant products such as Gonal‑F (FSH only) or Menopur (FSH + LH). Choice depends on protocol, patient response and clinician preference.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, use according to the manufacturer’s stability guidelines and discard any unused portion after the recommended period.

Meriofert is supplied as a sterile powder for injection. After reconstitution with the appropriate diluent, it is administered by a trained healthcare professional via intramuscular or subcutaneous injection, typically in the abdominal wall or thigh, following the dosing schedule prescribed by the treating physician.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and life‑threatening, multiple pregnancy, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of abdominal distension, rapid weight gain, shortness of breath, or severe pain, and treatment should be adjusted promptly.

Meriofert is contraindicated in individuals with known hypersensitivity to any component of the product, active ovarian cysts, uncontrolled thyroid disease, severe ovarian hyperstimulation syndrome, or in women who are already pregnant. Caution is also advised for patients with a history of thromboembolic disorders.